Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Oncotarget - 28 Jun 2016

Lee Michael S, Helms Timothy L, Feng Ningping, Gay Jason, Chang Qing Edward, Tian Feng, Wu Ji Y, Toniatti Carlo, Heffernan Timothy P, Powis Garth, Kwong Lawrence N, Kopetz Scott

Abstract excerpt

PURPOSE: Though the efficacy of MEK inhibitors is being investigated in KRAS-mutant colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy did not reveal significant antitumor activity. Resistance to MEK inhibitor monotherapy developed through a variety of mechanisms converging in ERK reactivation. Since ERK increases cyclin D expression and increases entry into the cell cycle, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to Extracellular Signal-Regulated MAP Kinases

Share to MAP Kinase Kinase Kinase 1

Share to Neoplasm Transplantation

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 27167191
DOI: 10.18632/oncotarget.9153
PMCID: PMC5129956

Genes

CDK4
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.PMID 27167191Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.Semantic proximity Read ↗

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.Semantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell LinesSemantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.Semantic proximity Read ↗

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read ↗

Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.